HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

TSCA Reform Needed, Stakeholders Agree, But Swift Passage Is Doubtful

This article was originally published in The Rose Sheet

Executive Summary

Although Sen. Frank Lautenberg, D-N.J., is committed to recasting the Toxic Substances Control Act during the 112th Congress, speakers at the GlobalChem Conference in Baltimore were doubtful that it would pass soon.

You may also be interested in...



Walgreens Launches Ology Personal Care Without “Harmful Chemicals”

Drugstore chain’s new line features “plant- and mineral-based” ingredients, carries an endorsement from Healthy Child Healthy World and is affordably priced. In promoting all that Ology is free of – including sulfates, parabens and phthalates – Walgreens suggests that better regulations are needed in the U.S. to ensure that consumers aren’t being exposed to “harmful chemicals.”

Toxic Substances Act Vote Could Come Soon – Lautenberg

Legislators, industry and others shared their views on updating the Toxic Substances Control Act at a Nov. 17 hearing of the Senate Environment and Public Works Committee’s Subcommittee on Superfund, Toxics and Environmental Health.

Lautenberg Bill Puts Chemical Safety Burden Of Proof On Industry

Legislation introduced in the Senate would update the Toxic Substances Control Act and set the responsibility for chemical safety substantiation squarely on manufacturers' shoulders.

Related Content

Latest News
See All
UsernamePublicRestriction

Register

RS017500

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel